For anyone who find themselves interested in the medical field but do not have the confident to be a doctor or a surgeon, but are keen to help others and do not have the phobia on the sight of blood, then a medical assistant might be the career which is suitable for you.

Before you sign up for a program or course for a medical assistant, let us visit some of the key advantages for being a medical assistant.

I. It is not an easy job, but it is a satisfying one which one will get the opportunities to help lots of helpless people who need medical attention and treatments. It is the fulfilling and satisfaction which one can gain from this career.

II. A certified medical assistant will get more opportunities compared to others to be promoted as a medical officers or supervisors with sound medical technology skills and expertise in hospitals or medical clinics if the candidate is performing well and proved him to be capable.

III. Due to the on-going expansion and advancement of the medical and health care industry, the demand for this medical profession is acute and highly required.

IV. A certified medical assistant is always preferred by the employers as compared to their peers whom have not being certified although it is not mandatory by law for one to get the certification at this stage. Nevertheless the ability to get one to be certified shows that the candidate is really committed and serious aabout his medical career.

V. Also within this job, one has to be very capable to solve and handle a wide variety of different administrative jobs as well as clerical jobs on daily basis. This is good for someone who loves to be responsible for multiple different tasks as this helps to aggregate the sense of satisfaction which he tend to obtain from this multitasking.

VI. A certified medical assistant should be able to be equipped with quality information that helps you to connect to the latest health care news and inventions as well as new threats.

VII. As medical assisting is ranked as one of the fastest growing occupations from now till 2016, its employment is expected to increase by at least 30%. The expansion of this health care industry with the new invention of immunizations and the aging of the population as well as the massive development in the medical technology has led to the rapid growing of the medical assisting job, which helps to open diverse opportunities for this profession in many medical facilities and fields.

We may wonder what is to become of the contact research organisation (CRO) industry while the economy slowly recovers from the recent recession but according to a recent report carried out by Frost & Sullivan, the CRO industry will continue to grow. During this current climate, biotech and pharma companies are less likely to rely on or invest in internal abilities to carry out their clinical trials. However, somebody has to do them...

The report has also warned that the "US CRO Markets-Key Therapeutic Areas" anticipate that struggling pharma and biotech companies will fail to meet the costs for trials currently underway. But this is not likely to be a lasting occurrence, suggests the report.

Senior industry analyst for Frost and Sullivan, Barath Shankar Subramanian revealed that the annual revenue growth for CROs has decreased from the 14-15% range to 10% this past year.

Although, this is not all bad news - Subramanian claims that the industry's annual revenues will double from now until the year 2015, growing from a current 12.91 billion to $22.87 billion in the years to come. This, he says, will be due to sponsor firms increasingly adopting tactical partnerships with smaller services firms or CROs. "After 10 years of talking about such relationships, CROs and pharma companies are beginning to forge them," he says.

Subramanian uses the immense Eli Lilly/Covance partnership as an example, which came in to effect in August last year, where Covance has outsourced $1.6 billion worth of drug development business to Lilly over the next 10 years.

"That's the flavor of the season," Subramanian says. "We're seeing some new models being explored when previously it was purely transactional, with CROs taking a wait and watch attitude toward strategic partnerships."

In addition, partnerships with CROs enable small sponsors more time within the research cycle to investigate promising molecules. Beginner biotech and pharma firms used to out-license their Phase I or Phase II; which resulted in a large amount of ambiguity for the future of the research study. In this day and age, conversely, more and more start-up firms are able to keep products in the pipeline for a longer period of time which in turn brings them closer to the market and this is due to the cost-effectiveness made possible by CROs. This is an optimistic outcome for the sponsor and the CRO.

The CDC strongly recommends that all members of the population receive the swine flu vaccine, particularly pregnant women and any children age 6 months and up, as well as anyone who cares for these high risk groups. Consumers, however, are leery of the swine flu vaccine, due to a complete lack of testing. In order to understand the potential risks behind getting the H1N1 vaccine, consumers can read the package insert for each formulation.

The U.S. Food and Drug Administration (FDA) provides package insert information for all four formulations of the H1N1 vaccine. The adults-only vaccine made by CSL Limited, the vaccine made by Novartis Vaccines and Diagnostics Limited, which is approved for ages 4 and up, the vaccine made by Sanofi Pasteur, Inc., which is approved for infants ages 6 months and up, and the intranasal vaccine, approved for toddlers age 2 and up, were all approved in September, 2009.

All safety and dosage information used for the H1N1 vaccine package insert is based on historical information about the seasonal influenza vaccine, but ingredient information is accurate. Among other ingredients, different formulations of the swine flu vaccine contain cancer-causing agents, mercury, and MSG. While most single-dose formulations of the H1N1 vaccine are mercury-free, the single-dose vials produced by Novartis do contain trace amounts of thimerosal. Most of the thimerosal, a mercury-based preservative, is removed by a purification process, but small amounts remain after processing.

Before making a choice about getting the swine flu vaccine, consumers should research, and get all the facts about the H1N1 vaccine.